Polar Capital’s Sarepta Therapeutics SRPT Stock Holding History

Polar Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40,000	Closed	-$5.16M	–	313
2019 Q4	$5.16M	Sell	40,000 -465,010	-92%	-$46.9M	0.04%	234
2019 Q3	$4.74M	Buy	505,010 +315,010	+166%	+$37.2M	0.04%	233
2019 Q2	$28.9M	Sell	190,000 -39,365	-17%	-$4.78M	0.25%	126
2019 Q1	$27.3M	Buy	229,365 +28,883	+14%	+$3.71M	0.25%	131
2018 Q4	$21.9M	Buy	200,482 +150,482	+301%	+$18.8M	0.23%	128
2018 Q3	$8.08M	Sell	50,000 -170,000	-77%	-$23.2M	0.07%	191
2018 Q2	$29.1K	Buy	+220,000	New	+$20.7M	0.18%	123
2018 Q1	–	Sell	-25,000	Closed	-$1.39M	–	276
2017 Q4	$1.39M	Buy	+25,000	New	+$1.32M	0.01%	240

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Polar Capital's SRPT Position: Q1 2020 in Review

Polar Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 40,000 shares — an estimated $5.16M sold.

Polar Capital first reported a position in SRPT in Q4 2017 and held it in 8 quarters. The position peaked at $28.9M in Q2 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

Polar Capital reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
Polar Capital sold 40,000 Sarepta Therapeutics shares in Q1 2020, an estimated $5.16M.
Polar Capital first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 8 quarters.
Polar Capital's Sarepta Therapeutics position peaked at $28.9M in Q2 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Polar Capital's 13F filing for Q1 2020, filed 15 May 2020.